Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. LFTO
2. CMCSA
3. QNT
4. NVDA
5. VRDN
6. INIO
7. DLR
8. HONA
9. ABBV
10. HON

Go back to Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results

Cowen Sees Favorable Risk/Reward in Endocyte (ECYT) Amid Phase III Trial of PSMA-617

February 27, 2018 3:33 PM EST

Endocyte, Inc. (NASDAQ: ECYT) recently announced that the commencement of a pivotal Phase III trial of its leading drug, PSMA-617, a radioligand therapeutic that targets the prostate-specific membrane antigen. This announcement, coming alongside the company's 4Q earnings, has prompted analysts at Cowen to... More